Advertisement

Use of Albumin-Cellulose Nitrate Microencapsulated Charcoal Hemoperfusion: in Acute Digoxin Toxicity in Dogs

  • S. Prichard
  • E. Chirito
  • A. Sniderman
  • T. M. S. Chang

Abstract

The incidence of digoxin toxicity remains high (1). The recognition of the role of the kidneys in digoxin excretion and consequently the need for reduced dosage in patients with impaired renal function has diminished, but not eliminated the risk of toxicity (2). Attempts to remove substantial quantities of digoxin by either peritoneal or hemodialysis have been unsuccessful due to their low clearance rates (3). Since the vast majority of digoxin is tissue bound, any dialysis method requires a high clearance rate from serum and rapid equilibration from the tissue to plasma compartments. Albumin-cellulose nitrate microencapsulated charcoal (ACAC) hemoperfusion has been shown to be successful in the treatment of certain drug intoxications (4) in addition to its use in renal failure (5,6). More recently, this approach has been used for digoxin intoxication (7,8,9). The present study examined the use of the ACAC microcapsule artificial kidney prepared as described earlier (10,11,12), in dogs made acutely toxic with intravenous digoxin.

Keywords

Serum Pool Royal Victoria Hospital Drug Intoxication Dialysis Method Digoxin Toxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ogilvie, R.I., Ruedy, J.: Can. Med. Assoc. J., 97:1450, 1967.PubMedGoogle Scholar
  2. 2.
    Evered, D.C., Chapman, C.: Br. Heart J., 33:540,1971.PubMedCrossRefGoogle Scholar
  3. 3.
    Ackerman, G.L., Doherty, J.E., Flannigan, W.J.: Ann. Int. Med., 67:718, 1967.PubMedGoogle Scholar
  4. 4.
    Chang, T.M.S., Coffey, J.F., Lister, C., Taroy, E., Stark, A.: Trans. Amer. Soc. Artif. Intern. Organs, 19: 87, 1973.CrossRefGoogle Scholar
  5. 5.
    Chang, T.M.S., Gonda, A., Dirks, J., Malave, N.: Trans. Amer. Soc. Artif. Intern. Organs, 17:246, 1971.Google Scholar
  6. 6.
    Chang, T.M.S.: Kidney Int., 10:S305, 1976.Google Scholar
  7. 7.
    Prichard, S., Chirito, E., Chang, T., Sniderman, A.D.: J. Clin. Invest. 409A, April, 1976.Google Scholar
  8. 8.
    Carvallo, A., Ramirez, B., Honig, H., Knepshield, J., Schreiner, G.E., Gelfand, M.C.: Trans. Amer. Soc. Artif. Organs, 22: 718, 1976.Google Scholar
  9. 9.
    Prichard, S., Chirito, E., Chang, T.M.S., Sniderman, A.D.: J. of Dialysis, 1:367, 1977.Google Scholar
  10. 10.
    Chang, T.M.S.: Can. J. Physiol. Pharmacol., 47:1043, 1969.PubMedCrossRefGoogle Scholar
  11. 11.
    Chang, T.M.S.: “Artificial Cells”, Charles C. Thomas, Publisher, Springfield, Illinois, 1972.Google Scholar
  12. 12.
    Chang, T.M.S.: Kidney Int., 10:S218, 1976.Google Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • S. Prichard
    • 2
  • E. Chirito
    • 1
  • A. Sniderman
    • 2
  • T. M. S. Chang
    • 1
  1. 1.Artificial Organs Research UnitMcGill University and Royal Victoria HospitalMontrealCanada
  2. 2.Cardiovascular Research UnitMcGill University and Royal Victoria HospitalMontrealCanada

Personalised recommendations